Stock Analysts

AAR Corp. (AIR) Progresses in MRO Business: Should You Hold?

Higher business activities leading to a rise in air traffic have been accelerating maintenance spending on aircraft, which is driving MRO services growth cycle and in turn boosting AAR Corp. ’s AIR business.This has helped the company to remain the largest independent maintenance, repair and overhaul (MRO) provider in North America. To expand its MRO business, the company has signed two contracts for heavy maintenance services with Air Canada in the fiscal second quarter […]

Stock Analysts

Rite Aid (RAD) Q3 Earnings Beat, Stores Transfer on Track

Rite Aid Corporation RAD reported third-quarter fiscal 2018 results, which marked a considerable improvement from the company’s recent trend. After posting in-line earnings last quarter, the company’s break-even results topped the Zacks estimate in the third quarter. Further, the company initiated the process of transferring stores and related assets in a phased manner to Walgreens Boots Alliance Inc. […]

Stock Analysts

7 Low Price-to-Sales Stocks to Buy for Optimum Returns

When considering valuation metrics, the obvious choice has always been Price-to-Earnings ratio as calculations based on earnings are easy and come in handy. However, Price-to-Sales has emerged as a convenient tool to determine the value of stocks that are incurring losses or are in an early cycle of development, generating meager or no profits. While a loss-making company with a negative Price-to-Earnings ratio falls out of investor favor, its Price-to-Sales could indicate the hidden strength of its business. […]

Stock Analysts

Will Higher Housing Demand Drive Lennar’s (LEN) Q4 Revenues?

Lennar Corporation LEN is set to report fourth-quarter fiscal 2017 results on Jan 10, before market open. Like other major homebuilding companies, Lennar has been reporting solid top-line numbers buoyed by strong demand for homes, favorable job market and impressive economic conditions. Miami-based homebuilder offers a diversified line of homes for first-time, move-up and active adult homebuyers […]

Stock Analysts

Neogen (NEOG) Q2 Earnings Beat Estimates, Revenues Miss

Neogen Corporation NEOG reported adjusted earnings of 33 cents per share in the second quarter of fiscal 2018. The figure beat the Zacks Consensus Estimate by 26.9% and increased 50% from the year-ago quarter. Revenues increased 12.2% on a year-over-year basis to $101.8 million, lagging the Zacks Consensus Estimate of $101.9 million by a slight margin […]

Stock Analysts

Enterprise to Expand Processing Capacity at Orla Facility

Enterprise Products Partners L.P. EPD intends to add a capacity of 300 million cubic feet per day (MMcf/d) at the cryogenic natural gas processing facility near Orla, Texas in Reeves County. A third processing train at Orla, scheduled to be commissioned in the second quarter of 2019, is expected to boost inlet volume capacity to 900 MMcf/d […]

Stock Analysts

TD Ameritrade or E*TRADE: Which Stock is a Better Pick?

TD Ameritrade Holding Corporation AMTD and E*TRADE Financial Corporation ETFC — the two investment brokers — have market capitalization of $28.9 billion and $13 billion, respectively. Being based in the same region, both companies are influenced by a similar economic environment. The Zacks Industry Rank is #38 (top 14% of the 250 plus Zacks industries) for the industry , to which these companies belong to […]

Stock Analysts

Novartis Gets Second Breakthrough Designation for Kisqali

Novartis AG NVS recently announced that the FDA has granted the Breakthrough Therapy designation to its breast cancer drug, Kisqali, for the initial endocrine-based treatment of pre- or peri-menopausal women with hormone-receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer, in combination with tamoxifen or an aromatase inhibitor. The above-mentioned designation is based on positive results from the MONALEESA-7 trial, wherein Kisqali, in combination with tamoxifen or an aromatase inhibitor as initial endocrine-based therapy, significantly prolonged progression-free survival (PFS) compared to endocrine therapy. […]